Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECTOR: Pre-operative Treatment in Resectable Colon Cancer
NCT06899477Phase 3Not yet recruiting
- Start
- Apr 2025
- Primary completion
- Apr 2033
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of oxaliplatin, fluorouracil, irinotecan, capecitabine in colon cancer, rectal cancer. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
oxaliplatinfluorouracilirinotecancapecitabine
03
Conditions
colon cancerrectal cancer
Beyond the preview
Go deeper on NCT06899477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06899477.